↓ Skip to main content

Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT

Overview of attention for article published in Leukemia, January 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (86th percentile)
  • Good Attention Score compared to outputs of the same age and source (65th percentile)

Mentioned by

twitter
10 X users
patent
4 patents

Citations

dimensions_citation
142 Dimensions

Readers on

mendeley
116 Mendeley
Title
Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT
Published in
Leukemia, January 2017
DOI 10.1038/leu.2017.16
Pubmed ID
Authors

M Neuenhahn, J Albrecht, M Odendahl, F Schlott, G Dössinger, M Schiemann, S Lakshmipathi, K Martin, D Bunjes, S Harsdorf, E M Weissinger, H Menzel, M Verbeek, L Uharek, N Kröger, E Wagner, G Kobbe, T Schroeder, M Schmitt, G Held, W Herr, L Germeroth, H Bonig, T Tonn, H Einsele, D H Busch, G U Grigoleit

Abstract

Cytomegalovirus (CMV) infection is a common, potentially life-threatening complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT). We assessed prospectively safety and efficacy of stem cell-donor- or third-party-donor-derived CMV-specific T cells for the treatment of persistent CMV infections after allo-HSCT in a phase I/IIa trial. Allo-HSCT patients with drug-refractory CMV infection and lacking virus-specific T cells were treated with a single dose of ex vivo MHC-Streptamer-isolated CMV epitope-specific donor T cells. 44 allo-HSCT patients receiving a T cell-replete (D(+)repl; n=28) or T cell-depleted (D(+)depl; n=16) graft from a CMV seropositive donor were screened for CMV-specific T cell immunity. 8 D(+)depl recipients received adoptive T cell therapy from their stem cell donor. CMV epitope-specific T cells were well supported and became detectable in all treated patients. Complete and partial virological response rates were 62.5 and 25%, respectively. Due to longsome third party donor (TPD) identification, only 8 of 57 CMV-patients transplanted from CMV seronegative donors (D(-)) received antigen-specific T cells from partially HLA-matched TPDs. In all but one, TPD-derived CMV-specific T cells remained undetectable. In summary, adoptive transfer correlated with functional virus-specific T cell reconstitution in D(+)depl patients. Suboptimal HLA-match may counteract expansion of TPD-derived virus-specific T cells in D(-) patients.Leukemia accepted article preview online, 16 January 2017. doi:10.1038/leu.2017.16.

X Demographics

X Demographics

The data shown below were collected from the profiles of 10 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 116 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Czechia 1 <1%
Unknown 115 99%

Demographic breakdown

Readers by professional status Count As %
Researcher 19 16%
Student > Ph. D. Student 13 11%
Other 11 9%
Professor 8 7%
Student > Master 7 6%
Other 25 22%
Unknown 33 28%
Readers by discipline Count As %
Medicine and Dentistry 34 29%
Immunology and Microbiology 14 12%
Agricultural and Biological Sciences 11 9%
Biochemistry, Genetics and Molecular Biology 7 6%
Engineering 3 3%
Other 8 7%
Unknown 39 34%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 February 2024.
All research outputs
#2,788,877
of 24,003,070 outputs
Outputs from Leukemia
#721
of 5,213 outputs
Outputs of similar age
#56,643
of 425,146 outputs
Outputs of similar age from Leukemia
#28
of 80 outputs
Altmetric has tracked 24,003,070 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,213 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.3. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 425,146 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 80 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.